PHILIPPINE HEART CENTER **INSTITUTIONAL ETHICS REVIEW BOARD**	Document Type **POLICY/STANDARD OPERATING PROCEDURE**	Document Code: POL-E-IRB-011
		Effective Date: January 2024
	Document Title **Reference**	Revision Number: 3
		Page: 1 of 3

REVISION HISTORY

Rev No.	Review Date	Description of Change	Date of Next Review
1	October 2018	Change of format	October 2019
2	July 2019	Change of format	July 2020
3	December 2020	Change of format	December 2021
4	January 2024	Change of format	January 2025

Reviewed by:	**MARIA TERESA B. ABOLA, MD** Deputy Executive Director for Education Training and Research Services	Approved by:	**JOEL M. ABANILLA, MD** Executive Director

1. Philippine Health Research Ethics Board Ad Hoc Committee on Updating the National Ethical Guidelines. National Ethical Guidelines for Research Involving Human Participants 2022. 2022.
2. Department of Health. Health Policy Development and Planning Bureau Health Research Division, Single Joint Research Ethics Board SJREB Standard Operating Procedures. 2021.
3. Philippine Health Research Ethics Board. 2020 PHREB Standard Operating Procedures. 2020.
4. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. 2013.
5. International Conference for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonized guidelines integrated addendum to ICH E6 (R1): guideline for Good Clinical Practice E6 (R2). Current step 4 version. 2016.
6. World Health Organization. WHO standard and operational guidance for ethics review of health – related research with human participants. 2011.
7. Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO). International ethical guidelines for health-related research involving humans. 2016.
8. Department of Health. Guidelines for the streamlined research ethics review process in the Department of Health. 2017.
9. Department of Health. Guidelines for the operationalization of the single joint ethics review process for multi-site researches in the Department of Health. 2017.
10. Ethical Guidelines for Biomedical research on Human Subjects, 2000.
11. Cavazos N., Forster D., and Bowen A.J., Ethical Concerns in Placebo-controlled studies: An Analytical Approach, Drug Information Journal 36(2) 2002: pp. 249-259, via WIRB documents
12. Code of Federal Regulation (CFR) 21, Volume 8, Part 812, April 2003, Food and Drug Administration, U.S. Government Printing Office via GPO Access
    - http://www.fda.gov/oc/ohrt/irbs/devrisk.pdf- Guidance for IRBs, Clinical Investigators and Sponsors regarding Significant Risk and Nonsignificant Risk Medical Device Studies
    - **http://www.fda.gov/oc/ohrt/irbs/irbreview.pdf - Guidance for IRBs, Clinical Investigators and Sponsors FAQ about Medical Devices**
    - **http://www.fda.gov/cdrh/ode/idepolcy.pdf - Guidance on IDE Policies and Procedures**
13. **Office of Human Research Protection (OHRP) regulations (45 CFR46)**
    - http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html).

Code of Federal Regulations for the Protection of Human Subjects in Research, U.S. Department of Health and Human Services, 1998, 21 CFR Part 50

- http://www.access.gpo.gov/nara/cfr/waisidx_98/21cfr50_98.html

14. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1977. Report and Recommendations: Research Involving Children. September 6.
15. Belmont Report 1979
16. European Commission (2001) *Directive 2001/20/EC of the European Parliament and of the Council*. Official Journal of the European Communities 1.5.2001 L124-44.http://europa.eu/eurlex/pri/en/oj/dat/2001/l_121/l_12120010501en00340044.pdf
17. Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies Guidance for Industry and Investigators . Safety Reporting Requirements for INDs and BA/BE Studies *U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) . Dec 2012 http://www.fda.gov/downloads/Drugs/.../Guidances/UCM227351.pdf*
18. Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval*.* *http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guies/default.htmdanc*
19. Guidance for IRBs, Clinical Investigator and Sponsors. IRB Continuing Review after Clinical Investigation approval. http://www.fda.gov/drugs/guidance
    - 21 CFR 56.111.
    - 21 CFR 56.109(a)
    - 21 CFR part 50, Subpart D.
20. Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval*.* *http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm*